Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 23.50
VRML's Cash to Debt is ranked higher than
70% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. VRML: 23.50 )
VRML' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 23.5

Equity to Asset 0.84
VRML's Equity to Asset is ranked higher than
88% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. VRML: 0.84 )
VRML' s 10-Year Equity to Asset Range
Min: -3.48   Max: 0.95
Current: 0.84

-3.48
0.95
Interest Coverage No Debt
VRML's Interest Coverage is ranked higher than
91% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. VRML: No Debt )
VRML' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -3.55
M-Score: -2.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -345.40
VRML's Operating margin (%) is ranked higher than
55% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. VRML: -345.40 )
VRML' s 10-Year Operating margin (%) Range
Min: -48250   Max: -61.47
Current: -345.4

-48250
-61.47
Net-margin (%) -343.69
VRML's Net-margin (%) is ranked higher than
55% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.34 vs. VRML: -343.69 )
VRML' s 10-Year Net-margin (%) Range
Min: -48368.18   Max: -49.38
Current: -343.69

-48368.18
-49.38
ROE (%) -32.95
VRML's ROE (%) is ranked higher than
59% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.54 vs. VRML: -32.95 )
VRML' s 10-Year ROE (%) Range
Min: -543.2   Max: -17.94
Current: -32.95

-543.2
-17.94
ROA (%) -28.78
VRML's ROA (%) is ranked higher than
59% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.87 vs. VRML: -28.78 )
VRML' s 10-Year ROA (%) Range
Min: -478.37   Max: -17.07
Current: -28.78

-478.37
-17.07
ROC (Joel Greenblatt) (%) -2266.75
VRML's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.91 vs. VRML: -2266.75 )
VRML' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8167.13   Max: -140.07
Current: -2266.75

-8167.13
-140.07
Revenue Growth (%) 2.90
VRML's Revenue Growth (%) is ranked higher than
66% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. VRML: 2.90 )
VRML' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 122.4
Current: 2.9

0
122.4
EBITDA Growth (%) -38.10
VRML's EBITDA Growth (%) is ranked higher than
54% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. VRML: -38.10 )
VRML' s 10-Year EBITDA Growth (%) Range
Min: -46.5   Max: 10.5
Current: -38.1

-46.5
10.5
EPS Growth (%) -38.80
VRML's EPS Growth (%) is ranked higher than
54% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. VRML: -38.80 )
VRML' s 10-Year EPS Growth (%) Range
Min: -47.5   Max: 9
Current: -38.8

-47.5
9
» VRML's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

VRML Guru Trades in Q2 2013

Jim Simons 372,300 sh (+7.98%)
» More
Q3 2013

VRML Guru Trades in Q3 2013

Jim Simons 324,900 sh (-12.73%)
» More
Q4 2013

VRML Guru Trades in Q4 2013

Jim Simons 282,400 sh (-13.08%)
» More
Q1 2014

VRML Guru Trades in Q1 2014

Jim Simons 282,200 sh (-0.07%)
» More
» Details

Insider Trades

Latest Guru Trades with VRML



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.00
VRML's P/B is ranked higher than
72% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. VRML: 4.00 )
VRML' s 10-Year P/B Range
Min: 1.46   Max: 62.61
Current: 4

1.46
62.61
P/S 25.84
VRML's P/S is ranked higher than
58% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.49 vs. VRML: 25.84 )
VRML' s 10-Year P/S Range
Min: 0.55   Max: 3381
Current: 25.84

0.55
3381
EV-to-EBIT 0.10
VRML's EV-to-EBIT is ranked higher than
53% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VRML: 0.10 )
VRML' s 10-Year EV-to-EBIT Range
Min: 12.7   Max: 87.5
Current: 0.1

12.7
87.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.20
VRML's Price/Net Cash is ranked higher than
95% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VRML: 4.20 )
VRML' s 10-Year Price/Net Cash Range
Min: 1.29   Max: 68.09
Current: 4.2

1.29
68.09
Price/Net Current Asset Value 4.10
VRML's Price/Net Current Asset Value is ranked higher than
93% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VRML: 4.10 )
VRML' s 10-Year Price/Net Current Asset Value Range
Min: 1.19   Max: 1200
Current: 4.1

1.19
1200
Price/Tangible Book 3.90
VRML's Price/Tangible Book is ranked higher than
81% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.12 vs. VRML: 3.90 )
VRML' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 53.24
Current: 3.9

0.9
53.24
Price/Median PS Value 2.50
VRML's Price/Median PS Value is ranked higher than
62% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. VRML: 2.50 )
VRML' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 287.5
Current: 2.5

0.13
287.5
Earnings Yield (Greenblatt) 1354.80
VRML's Earnings Yield (Greenblatt) is ranked higher than
97% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. VRML: 1354.80 )
VRML' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 3222.6
Current: 1354.8

1.1
3222.6
Forward Rate of Return (Yacktman) -79.20
VRML's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.73 vs. VRML: -79.20 )
VRML' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.4   Max: 7.5
Current: -79.2

3.4
7.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:CUL1.Germany
Vermillion, Inc., was originally incorporated in California on December 9, 1993, under the name Abiotic Systems. In March 1995, Abiotic Systems changed its corporate name to Ciphergen Biosystems, Inc. and on June 21, 2000, it reincorporated in Delaware. The Company is engaged in discovery; development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. It uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers for developing a procedure to measure a property or concentration of an analyte, known as an 'assay' and commercializing novel diagnostic tests. The Company's product, OVA1, was cleared by the United States Food and Drug Administration (FDA) on September 11, 2009. OVA1 addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The Company has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. In the field of peripheral arterial disease, it has identified candidate biomarkers that may help to identify individuals at high risk for a decreased ankle-brachial index score, which is indicative of the likely presence of peripheral arterial disease. It has recently completed an intended-use study to develop and validate a multi-marker algorithm for the assessment of individuals at risk for peripheral arterial disease. This algorithm will be specifically directed at a primary care population in which the peripheral arterial disease blood test (VASCLIR) is expected to be used. Current and former academic and research institutions that the Company has collaborations with include The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch 'UTMB'; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet, Copenhagen University Hospital; The Ohio State University Research Foundation; and Stanford University. The Company has been subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens and hazardous waste as well as to the safety and health of laboratory employees.
» More Articles for VRML

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
VERMILLION, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 24 2014
Vermillion appoints Dr. Judith Wolf as Chief Medical Officer Jun 17 2014
Vermillion Appoints Dr. Judith K. Wolf as Chief Medical Officer Jun 17 2014
VERMILLION, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation... Jun 16 2014
The Bakken Gets Bigger - Likely A LOT Bigger Jun 11 2014
VERMILLION, INC. Financials May 23 2014
VERMILLION, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial... May 16 2014
Vermillion's (VRML) CEO James LaFrance on Q1 2014 Results - Earnings Call Transcript May 15 2014
Vermillion, Inc. Earnings Call scheduled for 4:30 pm ET today May 15 2014
Vermillion (VRML) Q1 2014 Results - Earnings Call Webcast May 15 2014
VERMILLION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 15 2014
VERMILLION, INC. Files SEC form 10-Q, Quarterly Report May 15 2014
Vermillion Reports First Quarter 2014 Results May 15 2014
Q1 2014 Vermillion, Inc. Earnings Release - After Market Close May 15 2014
Moffitt Cancer Center and Vermillion Collaborate to Model Improvements in Ovarian Cancer Care... May 08 2014
Vermillion Sets First Quarter 2014 Conference Call for Thursday, May 15, 2014 May 01 2014
Vermillion Launches ASPiRA LABS Apr 28 2014
VERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Apr 23 2014
Vermillion Appoints Chairman of Board James LaFrance as President and Chief Executive Officer Apr 23 2014
VERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 18 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide